Nektar Therapeutics (NKTR) said Thursday that its experimental cancer treatment, NKTR-255, combined with durvalumab, sped up the recovery of immune cells in patients who had completed radiation therapy.
The interim analysis of the phase 2 study showed that NKTR-255 reversed radiation-induced lymphopenia in patients with locally advanced non-small cell lung cancer, according to the company.
Nektar said NKTR-255, when combined with durvalumab after radiation therapy, significantly improved the recovery of lymphocytes after 8 weeks compared to patients who received radiation therapy alone or radiation therapy with durvalumab.
Shares of the company were down 2.1% in recent trading.
Price: 1.37, Change: -0.02, Percent Change: -1.44
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。